Holen Sie sich die Stockscreener-App
20.43
1.40%
-0.29
Handel nachbörslich:
20.21
-0.22
-1.08%
Schlusskurs vom Vortag:
$20.72
Offen:
$20.49
24-Stunden-Volumen:
1.04M
Relative Volume:
0.59
Marktkapitalisierung:
$2.45B
Einnahmen:
$59.61M
Nettoeinkommen (Verlust:
$-262.14M
KGV:
-5.2117
EPS:
-3.92
Netto-Cashflow:
$-247.49M
1W Leistung:
-0.68%
1M Leistung:
+18.16%
6M Leistung:
+57.88%
1J Leistung:
+109.75%
1-Tages-Spanne:
$20.16
$20.61
1-Wochen-Bereich:
$19.76
$21.56
52-Wochen-Spanne:
$8.03
$21.56
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Firmenname
Arcutis Biotherapeutics Inc
Sektor
Branche
Telefon
805-418-5006
Adresse
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Vergleichen Sie ARQT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
20.43 | 2.48B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Eingeleitet | Goldman | Neutral |
| 2024-12-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-03 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-10-26 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-10-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-09-07 | Eingeleitet | Needham | Buy |
| 2022-03-17 | Eingeleitet | Goldman | Buy |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-05-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Hochstufung | Goldman | Neutral → Buy |
| 2020-10-08 | Eingeleitet | Truist | Buy |
| 2020-02-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Eingeleitet | Cowen | Outperform |
| 2020-02-25 | Eingeleitet | Goldman | Neutral |
| 2020-02-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Arcutis Biotherapeutics Inc Aktie (ARQT) Neueste Nachrichten
What the charts say about Arcutis Biotherapeutics Inc. today2025 Support & Resistance & Weekly Momentum Stock Picks - newser.com
Will a bounce in Arcutis Biotherapeutics Inc. offer an exitQuarterly Performance Summary & Daily Chart Pattern Signals - newser.com
How high can Arcutis Biotherapeutics Inc. stock goDollar Strength & Entry and Exit Point Strategies - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to Fed rate cutsQuarterly Growth Report & Consistent Profit Trading Strategies - newser.com
Can Arcutis Biotherapeutics Inc. hit a new high this monthWeekly Market Report & Reliable Price Breakout Alerts - newser.com
Should you wait for a breakout in Arcutis Biotherapeutics Inc.July 2025 Big Picture & Free Long-Term Investment Growth Plans - newser.com
Has Arcutis Biotherapeutics Inc. found a price floorJuly 2025 EndofMonth & Low Risk Entry Point Tips - newser.com
Is Arcutis Biotherapeutics Inc. stock poised for growth2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
How Arcutis Biotherapeutics Inc. stock reacts to inflationary pressuresJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Is Arcutis Biotherapeutics Inc. stock safe for conservative investorsJuly 2025 Weekly Recap & Capital Efficiency Focused Ideas - newser.com
How to interpret RSI for Arcutis Biotherapeutics Inc. stockJuly 2025 Movers & Technical Pattern Based Buy Signals - newser.com
Sentiment analysis tools applied to Arcutis Biotherapeutics Inc.Market Growth Report & Daily Market Momentum Tracking - newser.com
Is Arcutis Biotherapeutics Inc. stock dividend yield sustainableInflation Watch & Low Volatility Stock Recommendations - newser.com
Arcutis Biotherapeutics Hits New 52-Week High of $21.55 - Markets Mojo
Arcutis Biotherapeutics reaches milestone recognized by Nasdaq - Traders Union
Wealth Enhancement Advisory Services LLC Purchases Shares of 15,666 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Is Arcutis Biotherapeutics Inc. stock bottoming out2025 Price Momentum & Free Growth Oriented Trading Recommendations - newser.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Hits New 1-Year HighStill a Buy? - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock hits 52-week high at 21.3 USD - Investing.com
Mizuho raises Arcutis Biotherapeutics stock price target to $26 on Zoryve sales - Investing.com
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - BioSpace
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Raises Target Price to $26 - 富途牛牛
FDA approves ZORYVE cream for atopic dermatitis in young children By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $90,260.16 in Stock - MarketBeat
Arcutis Biotherapeutics Hits New 52-Week High of $21.30 - Markets Mojo
FDA Approves Roflumilast Cream 0.05% for Atopic Dermatitis in Children 2 to 5 - Drug Topics
Arcutis Biotherapeutics stock rises after FDA approves eczema cream for young children - Investing.com
ARQT: FDA Approves ZORYVE Cream for Young Children's Atopic Dermatitis - GuruFocus
FDA approves ZORYVE cream for atopic dermatitis in young children - Investing.com
Arcutis Biotherapeutics Announces FDA Approval of ZORYVE® Cream 0.05% for Treatment of Atopic Dermatitis in Children Aged 2 to 5 - Quiver Quantitative
1.8M U.S. children ages 2–5 treated topically — Arcutis' ZORYVE 0.05% FDA‑approved, available Oct 2025 - Stock Titan
Fishman Jay A Ltd. MI Purchases 23,000 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
What drives Arcutis Biotherapeutics Inc stock priceMarket Sentiment Extremes & Ride the Wave of Market-Beating Growth - earlytimes.in
Is Arcutis Biotherapeutics Inc. stock reversal real or fakeJuly 2025 PostEarnings & Real-Time Chart Breakout Alerts - newser.com
Arcutis Biotherapeutics (ARQT): Evaluating Valuation as Upward Earnings Revisions Fuel Renewed Investor Interest - Yahoo Finance
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 3.2% Following Insider Selling - Defense World
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 3.2% After Insider Selling - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Director Howard Welgus Sells 10,000 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 24,261 Shares - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Todd Watanabe Sells 20,739 Shares - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Arcutis Biotherapeutics reports inducement grants under Nasdaq Listing Rule - MarketScreener
94,500 RSUs Granted — Arcutis Reports Inducement Grants to 12 New Hires, Vesting Over Four Years - Stock Titan
Will Arcutis Biotherapeutics Inc. stock split attract more investorsOptions Play & Weekly Chart Analysis and Guides - newser.com
Arcutis Biotherapeutics Achieves 101.39% Stock Surge, Establishing It as a Multibagger Performer - Markets Mojo
Arcutis Biotherapeutics Hits New 52-Week High of $20.10, Up 162% - Markets Mojo
AMI Asset Management Corp Sells 94,839 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Revenues Not Telling The Story For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) After Shares Rise 27% - simplywall.st
Finanzdaten der Arcutis Biotherapeutics Inc-Aktie (ARQT)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.15%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):